{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:19:40Z","timestamp":1767676780673,"version":"3.48.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271735"],"award-info":[{"award-number":["82271735"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>As the latest drug available for the treatment of spinal muscular atrophy (SMA), real-world research data on risdiplam are still lacking. The purpose of this study was to supplement the real-world data in SMA children receiving risdiplam by studying children in multiple centers throughout China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 34 children with SMA were collected from September 2021 to November 2024 and followed for a period of 8.3\u2009\u00b1\u20094.6 months. The Children\u2019s Hospital of Philadelphia infant test of neuromuscular disorders (CHOPINTEND) scores of 18 children at the last visit improved when compared with baseline [20 (3\u201360) vs. 39 (8\u201361),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001]. Thirteen patients (76.5%) demonstrated a noticeable improvement in Hammersmith functional motor scale expanded (HFMSE) score at the last follow-up compared with baseline [22 (6\u201352) vs. 31 (8\u201359),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003]. Revised upper limb module (RULM) scores of 7 patients at the last follow-up were improved compared with those at baseline [21 (6\u201332) vs. 24 (9\u201335),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.018]. Improvements in motor function were monthly quantified by generalized estimating equation analysis. The CHOPINTEND score increased by 1.8 points\/month (95%CI 0.8 to 2.9,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) in children with short disease duration before treatment, 2.7 points\/month (95%CI 2.4 to 3.0,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) in children with type 1 and 2.7 points\/month (95%CI 2.1 to 3.3,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) in patients with 2 copies of survival motor neuron 2 gene. Pneumonia was the most frequently reported adverse event, whereas laboratory tests yielded no unusual findings.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Motor ability of children with SMA were improved under risdiplam with a good safety profile. The degree of motor function improvement was related to the course of disease before treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-03929-4","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T17:49:03Z","timestamp":1753984143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal efficacy of risdiplam treatment in Chinese children with spinal muscular atrophy"],"prefix":"10.1186","volume":"20","author":[{"given":"Yue","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danhui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xufeng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6736-1407","authenticated-orcid":false,"given":"Shanshan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"issue":"4","key":"3929_CR1","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40263-022-00910-8","volume":"36","author":"J Paik","year":"2022","unstructured":"Paik J, Risdiplam. A review in spinal muscular atrophy. CNS Drugs. 2022;36(4):401\u201310. https:\/\/doi.org\/10.1007\/s40263-022-00910-8","journal-title":"CNS Drugs"},{"issue":"5","key":"3929_CR2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2102047","volume":"385","author":"BT Darras","year":"2021","unstructured":"Darras BT, Masson R, Mazurkiewicz-Be\u0142dzi\u0144ska M, et al. Risdiplam-Treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med. 2021;385(5):427\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2102047","journal-title":"N Engl J Med"},{"issue":"1","key":"3929_CR3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","volume":"21","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Deconinck N, Mazzone ES, et al. Safety and efficacy of once-daily Risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2022;21(1):42\u201352. https:\/\/doi.org\/10.1016\/S1474-4422(21)00367-7","journal-title":"Lancet Neurol"},{"issue":"12","key":"3929_CR4","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","volume":"21","author":"R Masson","year":"2022","unstructured":"Masson R, Mazurkiewicz-Be\u0142dzi\u0144ska M, Rose K, et al. Safety and efficacy of Risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial. Lancet Neurol. 2022;21(12):1110\u20139. https:\/\/doi.org\/10.1016\/S1474-4422(22)00339-8","journal-title":"Lancet Neurol"},{"issue":"5","key":"3929_CR5","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1007\/s00415-023-11560-1","volume":"270","author":"M Oskoui","year":"2023","unstructured":"Oskoui M, Day JW, Deconinck N, et al. Two-year efficacy and safety of Risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). J Neurol. 2023;270(5):2531\u201346. https:\/\/doi.org\/10.1007\/s00415-023-11560-1","journal-title":"J Neurol"},{"issue":"1","key":"3929_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12883-024-03562-x","volume":"24","author":"B Bjelica","year":"2024","unstructured":"Bjelica B, Wohnrade C, Cespedes I, Osmanovic A, Schreiber-Katz O, Petri S. Risdiplam therapy in adults with 5q-SMA: observational study on motor function and treatment satisfaction. BMC Neurol. 2024;24(1):67. https:\/\/doi.org\/10.1186\/s12883-024-03562-x","journal-title":"BMC Neurol"},{"key":"3929_CR7","doi-asserted-by":"publisher","unstructured":"Sitas\u202fB, Hancevic\u202fM, Bilic\u202fK, Bilic\u202fH, Bilic\u202fE. Risdiplam real world data \u2013 looking beyond motor neurons and motor function measures. J Neuromuscul Dis. 2024;11(1):75\u201384. https:\/\/doi.org\/10.3233\/JND-230197","DOI":"10.3233\/JND-230197"},{"issue":"12","key":"3929_CR8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.17116\/jnevro2023123121148","volume":"123","author":"YA Shpilyukova","year":"2023","unstructured":"Shpilyukova YA, Illarioshkin SN. [Oral disease-modifying therapy for adult patients with spinal muscular atrophy type 2]. Zhurnal Nevrologii I Psikhiatrii Imeni SS Korsakova. 2023;123(12):148\u201353. https:\/\/doi.org\/10.17116\/jnevro2023123121148","journal-title":"Zhurnal Nevrologii I Psikhiatrii Imeni SS Korsakova"},{"key":"3929_CR9","doi-asserted-by":"publisher","first-page":"ddae052","DOI":"10.1093\/hmg\/ddae052","volume":"23","author":"K Ma","year":"2024","unstructured":"Ma K, Zhang K, Chen D, et al. Real-world evidence: Risdiplam in a patient with spinal muscular atrophy type I with a novel splicing mutation and one SMN2 copy. Hum Mol Genet Published Online March. 2024;23:ddae052. https:\/\/doi.org\/10.1093\/hmg\/ddae052","journal-title":"Hum Mol Genet Published Online March"},{"key":"3929_CR10","doi-asserted-by":"publisher","unstructured":"Yan Y, Feng Y, Jiang L, Jin J, Mao S. Safety of Risdiplam in spinal muscular atrophy patients after short-term treatment with Nusinersen. Muscle Nerve Published Online August. 2024;13. https:\/\/doi.org\/10.1002\/mus.28228","DOI":"10.1002\/mus.28228"},{"key":"3929_CR11","doi-asserted-by":"publisher","unstructured":"Zhao X, Liao Y, Zhao J, Zhu L, Liu J, Zhang M, et\u202fal. Motor function and safety of nusinersen and risdiplam in Asian patients with types\u202f2\u20134 spinal muscular atrophy (SMA): a systematic review and meta\u2011analysis.\u00a0Adv Ther.\u00a02025 Apr;42(4):1611\u20131626. https:\/\/doi.org\/10.1007\/s12325-024-03101-7","DOI":"10.1007\/s12325-024-03101-7"},{"issue":"2","key":"3929_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103\u201315. https:\/\/doi.org\/10.1016\/j.nmd.2017.11.005","journal-title":"Neuromuscul Disord"},{"issue":"18","key":"3929_CR13","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus Sham control in Infantile-Onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1702752","journal-title":"N Engl J Med"},{"issue":"7","key":"3929_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus Sham control in Later-Onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1710504","journal-title":"N Engl J Med"},{"issue":"9","key":"3929_CR15","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel RS, McDermott MP, Kaufmann P, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810\u20137. https:\/\/doi.org\/10.1212\/WNL.0000000000000741","journal-title":"Neurology"},{"issue":"1","key":"3929_CR16","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s13023-022-02455-x","volume":"17","author":"C Cances","year":"2022","unstructured":"Cances C, Vlodavets D, Comi GP, et al. Natural history of type 1 spinal muscular atrophy: a retrospective, global, multicenter study. Orphanet J Rare Dis. 2022;17(1):300. https:\/\/doi.org\/10.1186\/s13023-022-02455-x","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"3929_CR17","doi-asserted-by":"publisher","first-page":"e16517","DOI":"10.1111\/ene.16517","volume":"31","author":"G Coratti","year":"2024","unstructured":"Coratti G, Bovis F, Pera MC, et al. Long-term natural history in type II and III spinal muscular atrophy: a 4-year international study on the Hammersmith functional motor scale expanded. Eur J Neurol. 2024;31(12):e16517. https:\/\/doi.org\/10.1111\/ene.16517","journal-title":"Eur J Neurol"},{"issue":"8","key":"3929_CR18","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1007\/s12035-017-0831-9","volume":"55","author":"A Govoni","year":"2018","unstructured":"Govoni A, Gagliardi D, Comi GP, Corti S. Time is motor neuron: therapeutic window and its correlation with pathogenetic mechanisms in spinal muscular atrophy. Mol Neurobiol. 2018;55(8):6307\u201318. https:\/\/doi.org\/10.1007\/s12035-017-0831-9","journal-title":"Mol Neurobiol"},{"issue":"10","key":"3929_CR19","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","volume":"384","author":"G Baranello","year":"2021","unstructured":"Baranello G, Darras BT, Day JW, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384(10):915\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2009965","journal-title":"N Engl J Med"},{"key":"3929_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpn.2020.11.004","volume":"30","author":"D Osredkar","year":"2021","unstructured":"Osredkar D, J\u00edlkov\u00e1 M, Butenko T, et al. Children and young adults with spinal muscular atrophy treated with Nusinersen. Eur J Paediatr Neurol. 2021;30:1\u20138. https:\/\/doi.org\/10.1016\/j.ejpn.2020.11.004","journal-title":"Eur J Paediatr Neurol"},{"issue":"2","key":"3929_CR21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3233\/JND-230162","volume":"11","author":"N Cornell","year":"2024","unstructured":"Cornell N, Childs AM, Wraige E, et al. Risdiplam in spinal muscular atrophy: safety profile and use through the early access to medicine scheme for the paediatric cohort in great Britain. J Neuromuscul Dis. 2024;11(2):361\u20138. https:\/\/doi.org\/10.3233\/JND-230162","journal-title":"J Neuromuscul Dis"},{"issue":"6","key":"3929_CR22","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/acn3.51560","volume":"9","author":"JM Kwon","year":"2022","unstructured":"Kwon JM, Arya K, Kuntz N, et al. An expanded access program of Risdiplam for patients with type 1 or 2 spinal muscular atrophy. Ann Clin Transl Neurol. 2022;9(6):810\u20138. https:\/\/doi.org\/10.1002\/acn3.51560","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"3929_CR23","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s13023-022-02420-8","volume":"17","author":"A Hahn","year":"2022","unstructured":"Hahn A, G\u00fcnther R, Ludolph A, et al. Short-term safety results from compassionate use of Risdiplam in patients with spinal muscular atrophy in Germany. Orphanet J Rare Dis. 2022;17(1):276. https:\/\/doi.org\/10.1186\/s13023-022-02420-8","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"3929_CR24","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1177\/22143602241288087","volume":"11","author":"MR Ashrafi","year":"2024","unstructured":"Ashrafi MR, Babaee M, Hashemi Nazari SS, et al. Comparative efficacy of Risdiplam and Nusinersen in type 2 and 3 spinal muscular atrophy patients: A cohort study using real-world data. J Neuromuscul Dis. 2024;11(6):1190\u20139. https:\/\/doi.org\/10.1177\/22143602241288087","journal-title":"J Neuromuscul Dis"},{"key":"3929_CR25","unstructured":"Masson R, Mazurkiewicz-Be\u0142dzi\u0144ska M, Baranello G, et al. FIREFISH Parts 1 and 2: 48-month safety and efficacy of risdiplam in Type 1 SMA [conference presentation]. Presented at: 4th Scientific International Congress on Spinal Muscular Atrophy; 2024 Mar 14\u201316; Ghent, Belgium."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03929-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03929-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03929-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:09:55Z","timestamp":1767676195000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-025-03929-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3929"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03929-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"type":"electronic","value":"1750-1172"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"11 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received approval from the Ethics Committee of Children\u2019s Hospital, Zhejiang University School of Medicine and other participating center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"391"}}